|
answer text |
<p>The National Institute for Health and Care Excellence (NICE) is currently developing
guidance for the National Health Service on whether Enhertu can be recommended for
routine NHS funding, based on an assessment of the costs and benefits. The NICE was
unfortunately unable to recommend Enhertu as a clinically and cost-effective use of
NHS resources in its final draft guidance published on 5 March 2024. Stakeholders
have had an opportunity to appeal against the NICE’s draft recommendations, and the
NICE will consider any appeals through the established process, and will publish final
guidance in due course.</p>
|
|